Biotechnology and drug discovery: from bench to bedside.

作者: Yoav Avidor , Nicola J. Mabjeesh , Haim Matzkin

DOI: 10.1097/01.SMJ.0000066654.35645.F7

关键词:

摘要: New biotechnology and drug discovery technologies are facilitating the rapid expansion of clinical chest, empowering clinicians with a better understanding disease as well novel modalities for treating patients. Important research tools themes include genomics, proteomics, ligand-receptor interaction, signal transduction, rational design, biochips, microarrays. Emerging classes monoclonal antibodies, cancer vaccines, gene therapy, antisense strands, enzymes, proteins. In this article, we review these topics illustrate their potential impact by presenting an overview promising drugs in pipeline. Clinicians who use treatments must become familiar trends.

参考文章(96)
Alain Renaud, Zarin Kachra, Nathalie Mousseau, Denis Gingras, Richard Beliveau, Edith Beaulieu, Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Research. ,vol. 21, pp. 145- 155 ,(2001)
L L Nielsen, D C Maneval, P53 tumor suppressor gene therapy for cancer. Cancer Gene Therapy. ,vol. 5, pp. 52- 63 ,(1998)
Denis Gingras, Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills? Cancer and Metastasis Reviews. ,vol. 19, pp. 83- 86 ,(2000) , 10.1023/A:1026504500555
C. McNeil, Monoclonal antibodies progress to the next generation. Journal of the National Cancer Institute. ,vol. 87, pp. 1738- 1739 ,(1995) , 10.1093/JNCI/87.23.1738
Banerjee D, Genasense (Genta Inc). Current opinion in investigational drugs. ,vol. 2, pp. 574- ,(2001)
Mary Jane Cunningham, Genomics and proteomics Journal of Pharmacological and Toxicological Methods. ,vol. 44, pp. 291- 300 ,(2000) , 10.1016/S1056-8719(00)00111-8
Blundell Tl, Structure-based drug design. Nature. ,vol. 384, pp. 23- 26 ,(1996) , 10.1038/384023A0
Thelma Angeles, John Lamb, John T. Isaacs, Craig A. Dionne, Daniel J. George, Jitesh Jani, Chikara Murakata, Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Research. ,vol. 59, pp. 2395- 2401 ,(1999)
Antonio J. da Silva, Margot Brickelmaier, Gerard R. Majeau, Zhifang Li, Lihe Su, Yen-Ming Hsu, Paula S. Hochman, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. Journal of Immunology. ,vol. 168, pp. 4462- 4471 ,(2002) , 10.4049/JIMMUNOL.168.9.4462